Lexicon Pharmaceuticals Inc News - LXRX

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

Lexicon Pharmaceuticals to Host 2024 Investor Day

THE WOODLANDS, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today...

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today...

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today...

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

THE WOODLANDS, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today...

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

Commercial launch of INPEFA® (sotagliflozin) continues to progress. with increasing demand across the...

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX...

Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA

Preparations Underway for Resubmission of New Drug Application for Sotagliflozin as an Adjunct to Insulin...

Form 4 - Statement of changes in beneficial ownership of securities

BooDog 1 week ago

Almost added back in but want to see confirmation for bottom. Double bottoms can be tricky. But even so, long term I like this.

👍️0

BooDog 1 week ago

Zacks analysis.
https://www.zacks.com/stock/news/2256264/all-you-need-to-know-about-lexicon-lxrx-rating-upgrade-to-buy

Upgrading to buy while I'm watching for the gap to fill which may put this around 1.40's. We'll see. I think analysts are always late to the party but this report is actually pretty timely.

👍️0

BooDog 3 weeks ago

Quite the gap there if that's what you're looking at.

👍️0

glenn1919 4 weeks ago

LXRX.......................................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783

👍️0

dcaf7 2 months ago

Lexicon will resubmit an NDA for sotagliflozin for patients with type 1 diabetes and chronic kidney disease. Good news. FDA rejected an NDA for type 1 diabetes in 2019. Now they changed their mind but only for patients with T1D+CKD. According to today's company presentation, slide 10, this population makes 21% of adults with T1D, or ~357,000 patients. Not a big addition to current indication. However, it will be the first gliflozin approved for T1D. No competition.

👍️ 1

Awl416 2 months ago

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

👍️0

BooDog 2 months ago

Earnings expected next Thursday, a miss or a hit? Revenue a hit imo.

Form 4 filed

👍️0

jdheart101 2 months ago

200 July 2.5 calls @.88 . Be back soon !!!

👍️0

TIMGZ 3 months ago

INBS**** AS ALWAYS SUPER FAST COMPUTERS***WHALES***HEDGES FUNDS*** TRADERS MIGHT SURGE THE VOLUME AT A VERY HIGH FREQUENCY****

WITHIN MINUTES*****UPTREND

SEEMS SETTING UP NICELY FOR THAT

👍️0

BooDog 3 months ago

Still looking pretty good here. Did trim a few 2.38's thouigh. Not sure if we'll see a reset soon or not.

👍️0

glenn1919 3 months ago

LXRX..........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783

👍️0

jdheart101 3 months ago

Another 4000. @1.76

👍️0

Legend431 3 months ago

Oops

👍️0

jdheart101 3 months ago

I’m in today 9500 @1.49 1/23/24

👍️0

BooDog 5 months ago

Ready to see this rock and roll. Get the Christmas rally going!

https://www.inpefahcp.com/

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. Wikipedia
Stock price: LXRX (NASDAQ) $1.16 +0.01 (+1.32%)
Dec 6, 10:18?AM EST - Disclaimer
Headquarters: The Woodlands, TX
CEO: Lonnel Coats (Jul 7, 2014–)
Revenue: 324.1 million USD (2019)
Number of employees: 225 (2011)
Founded: 1995, The Woodlands, TX
Founder: Arthur T Sands
Subsidiaries: Lex-Gen Woodlands, L.P., Lexicon Pharmaceuticals (New Jersey), Inc
Product
https://www.lexpharma.com/

https://www.lexpharma.com/media-center/news

👍️0

BooDog 5 months ago

Insider buying... Director Philippe Amouyal's Strategic 200,000 Share Purchase in Lexicon Pharmaceuticals Inc

https://finance.yahoo.com/news/director-philippe-amouyals-strategic-200-060356510.html?guccounter=1&guce_referrer=aHR0cHM6Ly9maW52aXouY29tLw&guce_referrer_sig=AQAAAIoi6pMjBlhAAWCTqsgFDgJ_L3Mq27MaOD9VoCvqo193rq8IznDFhr2okgZCfdpTcOoOQpbq-htdQ0dRd_C7SPjLqq1-XLfxoxxNvrWLXCfYfWwGJkWm40NnRnChJ7IS-3NNjcnArKcxghtaIU9gZcRtqotAVRnZUPj9phWfJymM

👍️0

Monksdream 5 months ago

LXRX new 52 week low

👍️0

BooDog 6 months ago

$LXRX. Looking good. See this in a week or 2.

JMHO.

👍️0

glenn1919 6 months ago

LXRX................................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783

👍️0

TRADER99 7 months ago

Looks like we saw a bottom here with this spike in volume

👍️0

Monksdream 7 months ago

LXRX new 52 week low

👍️0

BooDog 7 months ago

Guess I wasn't watching the board here Monk. Have been watching the chart though and have been accumulating around 1.10' last week and added today.

Cheers

👍️0

Monksdream 7 months ago

LXRX new 52 week low

👍️0

Monksdream 7 months ago

LXRX new 52 week low

👍️0

Monksdream 7 months ago

LXRX new 52 week low

👍️0

Monksdream 7 months ago

LXRX new 52 week low

👍️0

BooDog 9 months ago

LXRX 1.70's. Watching.

👍️0

BooDog 10 months ago

$LXRX https://finance.yahoo.com/news/lexicon-announces-planned-advancement-lx9211-004500120.html
Conference call this morning...

Conference Call and Webcast Information

Lexicon management will hold a live conference call and webcast Monday, June 26, 2023, at 8:00 am ET / 7:00 am CT. The dial-in number for the conference call is 888-317-6003 and the conference ID for all callers is 7186279. The live webcast and replay may be accessed by visiting Lexicon’s website at www.lexpharma.com/events. An archived version of the webcast will be available on the website for 14 days.

Quite the boost for institutionals.
https://www.sec.gov/Archives/edgar/data/1062822/000119312523160877/d449914dsc13da.htm

👍️0

BooDog 11 months ago

Agree. Too easy here. So predictable they'd be doing an offering though. Easy peasy this one is.
Taking nibbles in the 2.50's. Should have sold more on the highs yesterday.

👍️0

TIMGZ 11 months ago

LXRX MIGHT NOT BE LOOKING BACK AGAN, FDA APPROVED DRUG AND ALL BIG PHARMA EYEING. MY OPINION *******
ONE PAID $260M FOR BACKING OUT, NOW LOOK AT LXRX

👍️ 1

BooDog 11 months ago

2.75 support. See how it holds, or not. Interesting sell off.

👍️0

glenn1919 11 months ago

LXRX.........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783

👍️0

BooDog 11 months ago

Hey there Glenn. This puppy has been excellent. Certainly one to keep an eye on.

👍️0

glenn1919 11 months ago

LXRX...........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783

👍️0

BooDog 12 months ago

If I se what I think I see, there's a reason shorts are leaving this puppy alone.

Added back in this morning but when something starts really moving you always say in hindsight that you should have bought more.

👍️0

glenn1919 12 months ago

LXRX.............................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783

👍️0

BooDog 12 months ago

High 2.96. Trip and rip potential. That's when the chart show either a tripple bottom or a tripple top and breaks through with some serious momentum.

See what this puppy does.

https://www.barchart.com/stocks/quotes/hils/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=LXRX&grid=1&height=210&studyheight=100

Let's get the move on.

👍️0

BooDog 1 year ago

PUDUFA coming in a couple months. Looks like they're pretty confident.

GLTA

👍️0

makinezmoney 1 year ago

$LXRX: Time to load July $3 calls...... now $0.70

Why ????

1. Cash on Hand.............. $138.4Milly
2. Huge Insider buying of shares of $45Milly at $2.50sh
3. Piper Sandler with $10 Overweight assigned back in August last year
4. PDUFA coming in MAY
5. Largest OI is 1k on the July $3 calls

You know what that means right ???? They gotta a good feeling about that PDUFA
$LXRX now at $2.44......... last time it spiked ffrom $1.12 to $9.50 from Nov6,2020 to
Feb1, 2021 ..... 9x bagger !

Round 2 coming

GO $LXRX

👍️0

BooDog 1 year ago

Chart showing some strength. Closes over 2.20 and the bulls will be in the lead for next week imo.

LXRX daily

👍️0

BooDog 2 years ago

Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022

THE WOODLANDS, Texas, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the following two oral presentations relating to its investigational drug LX9211 will be delivered virtually during the World Brain Disorders and Neuroscience Summit 2022 Hybrid in Munich, Germany:

“Evaluation of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain: Study Design and Topline Results from the RELIEF-DPN-1 Trial”, describes the positive results achieved in this proof-of-concept study and will be given on Saturday, October 29th at 3:25pm CEST/9:25am ET.

“Evaluation of LX9211, a Potent, Selective Inhibitor of AAK1, in Preclinical Models of Spasticity”, describes the effect of LX9211 in reducing spasticity in established animal models and will be given on Monday, October 31st at 3:35pm CET/8:35am ET.

https://finance.yahoo.com/news/lexicon-pharmaceuticals-announces-oral-presentations-125900260.html

Looks to be waking up.

LXRX chart

👍️0

BooDog 2 years ago

Bears are on the job. eom

LXRX chart

Message in reply to:
Bear flag forming. And right before the golden cross. Waiting to add.

Thinking 2.45 - 2.50 support may hold. Though depending on what really happens the $2 support looks stronger.

I'm looking for around $2. This looks like it's only starting to crack. Of course, news AND SOME VOLUME!!!! would certainly help.

No one answered me about the bear flag. So not sure if anyone did anything.

👍️0

BooDog 2 years ago

Bear flag forming. And right before the golden cross. Waiting to add.

Thinking 2.45 - 2.50 support may hold. Though depending on what really happens the $2 support looks stronger.

LXRX daily

All imo of course.

👍️0

BooDog 2 years ago

Nice to see the volume maintaining. Hope some were able to take advantage advantage of the dip.

👍️0

BooDog 2 years ago

Nice!! Get'r done LXRX!

👍️0

BooDog 2 years ago

Watching the reset. Told you this a great swing play stock.

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Lexicon Pharmaceuticals Inc (LXRX)

Get an advanced news scanner tailored to your needs by ADVFN

LXRX News

Lexicon Pharmaceuticals to Host 2024 Investor Day

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

LXRX Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Lexicon Pharmaceuticals Inc (LXRX) News

Lexicon Pharmaceuticals Inc (LXRX)

Get an advanced news scanner tailored to your needs by ADVFN

LXRX News

Lexicon Pharmaceuticals to Host 2024 Investor Day

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

LXRX Discussion

Your Recent History

Company

Business

Popular

Get The App